Table 2 Influencing Factors– Univariate Logistic Regression Analysis

Gender (Female, n = 120)

446

 Male

326

1.081

[0.710–1.646]

0.717

Age group (> 75, n = 66)

446

  ≤ 30

6

0.000

[0.000–0.000]

.

 31–45*

22

0.059

[0.016–0.224]

< 0.001*

 46–65*

243

0.253

[0.139–0.461]

< 0.001*

 66–75*

109

0.426

[0.221–0.825]

0.011*

Marital status (Single, n = 55)

436

 Married*

298

4.221

[2.099–8.488]

< 0.001*

 Divorced*

13

3.000

[1.171–7.684]

0.022*

 Widowed*

35

3.778

[1.482–9.631]

0.005*

 Permanent partnership*

13

6.400

[1.748–23.438]

0.005*

Education level (Academic, n = 48)

243

1.155

[0.607–2.200]

0.661

At least one comorbidity (Yes)

401

2.372

[1.501–3.750]

0.001*

Cardiovascular comorbidity (Yes)

446

1.593

[1.087–2.334]

0.017*

Pulmonal comorbidity (Yes)

446

1.058

[0.620–1.804]

0.836

Neurological comorbidity (Yes)

446

1.232

[0.673–2.255]

0.500

Oncological comorbidity (Yes)

446

1.235

[0.790–1.931]

0.355

Regular medication (Yes)*

401

2.372

[1.501–3.750]

< 0.001*

Living environment (Living independent at home, n = 357)

411

 At home with support

49

1.172

[0.645–2.130]

0.603

 Care facility

5

0.281

[0.031–2.541]

0.259

Religion (Protestant, n = 182)

413

 Roman-catholic

173

0.752

[0.495–1.141]

0.181

 Muslim

5

0.000

[0.000–0.000]

0.999

 Other religion

27

0.744

[0.508–2.581]

0.744

 Atheist

26

0.672

[0.293–1.541]

0.348

Religiosity (Yes)

387

1.288

[0.577–2.876]

0.536

Cancer location (oral cavity & oropharynx, n = 147)

446

 Hypopharynx & larynx

116

1.069

[0.656–1.742]

0.789

 Nose & nasopharynx

34

0.760

[0.354–1.631]

0.481

 Salivary glands

61

1.446

[0.794–2.634]

0.227

 Other head and neck cancer entities

72

1.227

[0.686–2.159]

0.477

 Multi-tier carcinoma

16

0.558

[0.185–1.686]

0.301

Secondary malignancies^a (No, n = 360)

432

 Yes, synchronous

18

0.827

[0.321–2.133]

0.695

 Yes, metachronous

54

0.662

[0.372–1.177]

0.160

Recurrence of cancer (No, n = 395)

437

 Loco-regional recurrence

39

1.003

[0.519–1.941]

0.993

 Distant metastases

3

0.585

[0.053–6.506]

0.663

UICC stadium (Stadium IV, n = 119)

385

 0

6

0.492

[0.087–2.787]

0.423

 I

132

0.702

[0.426–1.157]

0.165

 II

67

0.797

[0.437–1.454]

0.460

 III

61

0.834

[0.449–1.549]

0.566

ECOG performance status (Stadium 0, n = 289)

386

 1

74

1.255

[0.753–2.093]

0.383

 2

21

2.973

[1.122–7.880]

0.028*

 3

2

1.189

[0.074–19.200]

0.903

Applied therapy (Surgery, n = 171)

446

 Primary surgery plus adjuvant therapy

198

1.168

[0.775–1.761]

0.497

 Definitive radiochemotherapy

71

0.823

[0.470–1.442]

0.457

 Salvage surgery

6

0.596

[0.106–3.342]

0.556

Time between initial diagnosis and survey period (120+ months, n = 63)

446

 0–12 months

113

1.104

[0.594–2.051]

0.754

 13–60 months

178

1.020

[0.572–1.819]

0.945

 61–120 months

92

1.250

[0.657–2.379]

0.497